In Israel, the mutation in the BRCA1 gene is particularly common among Jews of Ashkenazi descent, hence a large proportion of the women have a high breast cancer risk. With ProFound AI Risk, we will be available to get an accurate short term risk evaluation for each woman with her mammography screening and personalize their follow-up so we can catch the cancer the earlier as possible,” stated a spokesperson from CLALIT. "We are thrilled to partner with CLALIT Health Services to introduce our advanced AI solutions to their network of hospitals. ProFound AI for DBT and ProFound AI Risk will empower radiologists and clinicians with state-of-the-art tools to detect breast cancer early, enhance patient outcomes, and provide personalized care," commented spokesperson from iCAD.

Dr. Ahuva Grobshtein, Head of Breast Radiology, Rabin MC

As a radiology specialist, I highly recommend that every radiologist integrate the iCAD system into their work. Like any new tool, it takes some time to get used to, but very quickly one learns the system’s “language” and realizes how beneficial it is.

At times, iCAD may highlight findings that seem exaggerated or less relevant, but with experience one learns to distinguish when it indicates something truly significant. The system does not replace the radiologist’s judgment; rather, it serves as a supportive tool that provides an additional layer of confidence, especially under heavy workloads.

Personally, I prefer to first review the study on my own and only then activate iCAD. In this way, it becomes a “second check” for me—a kind of additional insurance that brings reassurance and confidence.

The greatest advantage is the sense that we are moving forward with the medicine of the future. Working with iCAD gives the feeling of being part of something larger—an innovative technology that empowers us without replacing us. It is like putting on a “Superman suit”: a tool that helps us avoid missing lesions or important findings, while keeping full control over the final decision.

Ultimately, iCAD has become my “new colleague” in the reading room—a smart assistant that strengthens professional confidence and supports the quality of diagnosis.

DR. MAIA ROSENTHAL-GILADIHead of the Breast Imaging Department, Soroka University Medical Center, Be’er Sheva.

In Israel, the mutation in the BRCA1 gene is particularly common among Jews of Ashkenazi descent, hence a large proportion of the women have a high breast cancer risk. With ProFound AI Risk, we will be available to get an accurate short term risk evaluation for each woman with her mammography screening and personalize their follow-up so we can catch the cancer the earlier as possible,” stated a spokesperson from CLALIT. "We are thrilled to partner with CLALIT Health Services to introduce our advanced AI solutions to their network of hospitals. ProFound AI for DBT and ProFound AI Risk will empower radiologists and clinicians with state-of-the-art tools to detect breast cancer early, enhance patient outcomes, and provide personalized care," commented spokesperson from iCAD.

Dr. Ahuva Grobshtein, Head of Breast Radiology, Rabin MC

In Israel, the mutation in the BRCA1 gene is particularly common among Jews of Ashkenazi descent, hence a large proportion of the women have a high breast cancer risk. With ProFound AI Risk, we will be available to get an accurate short term risk evaluation for each woman with her mammography screening and personalize their follow-up so we can catch the cancer the earlier as possible,” stated a spokesperson from CLALIT. "We are thrilled to partner with CLALIT Health Services to introduce our advanced AI solutions to their network of hospitals. ProFound AI for DBT and ProFound AI Risk will empower radiologists and clinicians with state-of-the-art tools to detect breast cancer early, enhance patient outcomes, and provide personalized care," commented spokesperson from iCAD.

Dr. Ahuva Grobshtein, Head of Breast Radiology, Rabin MC